^
    1d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    3d
    Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies (clinicaltrials.gov)
    P=N/A, N=63, Not yet recruiting, Ipsen
    New trial • Real-world evidence
    |
    Tazverik (tazemetostat)
    3d
    Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, Washington University School of Medicine | Trial completion date: May 2031 --> Apr 2029 | Trial primary completion date: May 2026 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    6d
    Pembrolizumab in Neoplasms or Lymphomas (clinicaltrials.gov)
    P2, N=18, Suspended, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Mar 2026
    Trial completion date
    |
    Keytruda (pembrolizumab)
    6d
    Nodal T-follicular helper cell lymphoma with hodgkin/reed-sternberg-like cells: Clinicopathologic and molecular characterization of 11 cases. (PubMed, Pathol Res Pract)
    AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase) • BRD4 (Bromodomain Containing 4)
    |
    TET2 mutation • TNFRSF8 positive • TNFRSF8 expression
    |
    CART-30
    7d
    KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Calquence (acalabrutinib)
    8d
    Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. (PubMed, World J Gastroenterol)
    Comparative insights highlight the advantages of liso-cel over other CAR-T cell products, such as axicabtagene ciloleucel and tisagenlecleucel in terms of toxicity, logistics, and outpatient feasibility. With ongoing improvements in manufacturing, accessibility, and biomarker development, liso-cel is well-positioned to become a central component in the evolving treatment paradigm for FL. However, challenges remain regarding durability of response, cost, and access, which warrant careful discussion.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T)
    8d
    Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol. (PubMed, Adv Radiat Oncol)
    Secondary endpoints include patient-reported quality of life (FACIT-Fatigue scale), response rate at 3 months posttreatment (Lugano criteria), local control, relapse-free survival, and overall survival. Exploratory analyses will evaluate financial toxicity (COST-FACIT questionnaire), health care expenditure, late toxicity, and the prognostic value of preradiation metabolic imaging parameters, including metabolic tumor volume, total lesion glycolysis, and maximum standardized uptake value, as well as molecular biomarkers such as TP53, MYC, and Ki-67.
    Clinical • P2 data • Journal
    |
    TP53 (Tumor protein P53)
    8d
    Reduced Activity of Soluble Fibroblast Activation Protein (sFAP) Represents a Biomarker of Aggressive Disease in Lymphoid Malignancies. (PubMed, Int J Mol Sci)
    Interestingly, measuring intratumoral FAP levels revealed an inverse pattern, with diffuse large B-cell lymphoma showing higher tissue FAP localization compared with follicular lymphoma (p < 0.001). These findings provide new insights into the biological and clinical significance of FAP in lymphoid malignancies, particularly highlighting the importance of sFAP activity as a potential prognostic marker in aggressive lymphoid malignancies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    8d
    Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=29, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    8d
    Long-term Follow up Local Registry Study of Kymriah in South Korea (clinicaltrials.gov)
    P=N/A, N=179, Recruiting, Novartis Pharmaceuticals | N=500 --> 179
    Enrollment change
    |
    Kymriah (tisagenlecleucel-T)